This website is for US healthcare professionals


Log In to Bolder Science


Don't have an account? Sign Up


Please enter your email address.

You will receive a link to create a new password via email.

Log In


Create an Account

  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

  • identifier


  • Recruitment Status

    Enrolling by invitation

  • First Posted

    April 24, 2019

  • Last update posted

    May 25, 2021

Study Description

Brief summary:

The purpose of this study is to enable patients with solid tumors, who received anetumab ravtansine in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. The patients will be observed to collect information on how safe and efficient the drug is.

  • Condition or Disease:Cancer
  • Intervention/Treatment: Drug: BAY94-9343 (Anetumab ravtansine)
  • Phase: Phase 2

Detailed Description

The primary objective of the study is to collect long-term safety information on anetumab ravtansine and to enable patients, who received an anetumab ravtansine-containing treatment in any Bayer-sponsored anetumab ravtansine parent study, to continue the treatment. The secondary objective is to further investigate the efficacy of the drug.

Study Design

  • Study Type: Interventional
  • Estimated Enrollment: 20 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: An Open-label, Multicenter Rollover Study to Provide Continued Treatment With Anetumab Ravtansine for Participants With Solid Tumors Who Were Enrolled in Previous Bayer-sponsored Studies
  • Actual Study Start Date: June 2019
  • Estimated Primary Completion Date: October 2024
  • Estimated Study Completion Date: October 2024

Arms and interventions

Arm Intervention/treatment
Experimental: Cancer patients
Adult patients with solid cancer who received anetumab-ravtansine treatment in a completed Bayer study
Drug: BAY94-9343 (Anetumab ravtansine)
BAY94-9343 (Anetumab ravtansine) will be administered as specified in the parent studies

Outcome Measures

  • Primary Outcome Measures: 1. Incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: Up to 5.5 years ]
  • 2. Incidence of treatment-emergent serious adverse events (TESAEs) [ Time Frame: Up to 5.5 years ]
  • 3. Incidence of drug-related TEAEs [ Time Frame: Up to 5.5 years ]
  • 4. Incidence of drug-related TESAEs [ Time Frame: Up to 5.5 years ]
  • Secondary Outcome Measures: 1. Overall survival [ Time Frame: Up to 5.5 years ]

Eligibility Criteria

  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No


Inclusion Criteria:

- Participants ongoing in an applicable Bayer-sponsored anetumab ravtansine parent study
at the time of its planned study closure.

- For on-treatment participants: participant is eligible to receive the next dose of
study intervention per the parent study protocol.

Exclusion Criteria:

- For on-treatment participants: a positive serum pregnancy test.

- For on-treatment participants: use of one or more of the prohibited medications listed
in the respective parent study protocol.

- Participants who are receiving standard-of-care agent(s) but not anetumab ravtansine
in the parent study, and are able to receive standard-of-care agent outside of the
clinical study.

Contacts and Locations



United States, Illinois
University of Chicago

United States, Maryland
National Cancer Institute

United States, Tennessee
Sarah Cannon Research Institute

United States, Texas
Mary Crowley Medical Research Center

Hôpital de la Timone - Marseille

Italy, Lombardia
ASST Grande Ospedale Metropolitano Niguarda

Szpital Wojewodzki W Szczecinie Zdunowie

Sponsors and Collaborators


More Information

  • Responsible Party: Bayer
  • Identifier: NCT03926143 History of Changes
  • Other Study ID Numbers: 20322, 2019-000061-20
  • First Posted: April 24, 2019 Key Record Dates
  • Last Update Posted: May 25, 2021
  • Last Verified: May 2021
  • Individual Participant
    Data (IPD) Sharing

  • Plan to Share IPD: Undecided
  • Plan Description: Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Bayer: Solid tumors